Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Operating Leases (2019 - 2025)

UroGen Pharma's Operating Leases history spans 7 years, with the latest figure at $6.1 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 270.36% year-over-year to $6.1 million; the TTM value through Dec 2025 reached $6.1 million, up 270.36%, while the annual FY2025 figure was $6.1 million, 270.36% up from the prior year.
  • Operating Leases reached $6.1 million in Q4 2025 per URGN's latest filing, down from $6.2 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $6.2 million in Q3 2025 to a low of $277000.0 in Q1 2022.
  • Average Operating Leases over 5 years is $2.0 million, with a median of $1.8 million recorded in 2022.
  • Peak YoY movement for Operating Leases: plummeted 82.45% in 2021, then skyrocketed 755.96% in 2023.
  • A 5-year view of Operating Leases shows it stood at $398000.0 in 2021, then soared by 534.92% to $2.5 million in 2022, then plummeted by 66.6% to $844000.0 in 2023, then surged by 95.85% to $1.7 million in 2024, then soared by 270.36% to $6.1 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Operating Leases are $6.1 million (Q4 2025), $6.2 million (Q3 2025), and $3.4 million (Q2 2025).